HC Wainwright Predicts Ardelyx’s Q1 Earnings (NASDAQ:ARDX)

Ardelyx, Inc. (NASDAQ:ARDX) – Equities research analysts at HC Wainwright cut their Q1 2025 EPS estimates for Ardelyx in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst E. Arce now forecasts that the biopharmaceutical company will post earnings of ($0.15) per share for the quarter, down from their prior estimate of ($0.05). HC Wainwright currently has a “Neutral” rating and a $5.50 target price on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Ardelyx’s Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.47) EPS, FY2026 earnings at $0.03 EPS, FY2027 earnings at $0.63 EPS and FY2028 earnings at $1.06 EPS.

Several other equities research analysts have also recently weighed in on ARDX. Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Ardelyx in a research report on Friday, August 2nd. Citigroup dropped their target price on shares of Ardelyx from $12.00 to $10.00 and set a “buy” rating for the company in a report on Monday, November 4th. Finally, StockNews.com raised shares of Ardelyx from a “sell” rating to a “hold” rating in a report on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.42.

Ardelyx Trading Down 6.2 %

Shares of Ardelyx stock opened at $4.59 on Wednesday. Ardelyx has a 52-week low of $3.49 and a 52-week high of $10.13. The firm has a 50-day moving average of $6.01 and a 200-day moving average of $6.29. The company has a debt-to-equity ratio of 0.64, a quick ratio of 3.87 and a current ratio of 4.03. The stock has a market cap of $1.09 billion, a PE ratio of -15.30 and a beta of 0.92.

Insider Activity

In other Ardelyx news, insider David P. Rosenbaum sold 20,000 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $5.94, for a total transaction of $118,800.00. Following the completion of the sale, the insider now owns 356,479 shares of the company’s stock, valued at approximately $2,117,485.26. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Ardelyx news, insider David P. Rosenbaum sold 20,000 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $5.94, for a total transaction of $118,800.00. Following the completion of the sale, the insider now owns 356,479 shares of the company’s stock, valued at approximately $2,117,485.26. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider David P. Rosenbaum sold 20,507 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $6.00, for a total value of $123,042.00. Following the transaction, the insider now owns 158,502 shares in the company, valued at $951,012. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 267,983 shares of company stock valued at $1,632,802 over the last quarter. 5.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Ardelyx

A number of large investors have recently modified their holdings of the company. Nisa Investment Advisors LLC increased its position in shares of Ardelyx by 1,026.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,548 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 3,233 shares during the last quarter. Redwood Wealth Management Group LLC purchased a new stake in shares of Ardelyx during the 2nd quarter valued at $62,000. Coastal Bridge Advisors LLC purchased a new stake in shares of Ardelyx during the 2nd quarter valued at $74,000. Helen Stephens Group LLC purchased a new stake in shares of Ardelyx during the 3rd quarter valued at $76,000. Finally, Paloma Partners Management Co purchased a new stake in shares of Ardelyx during the 1st quarter valued at $86,000. 58.92% of the stock is currently owned by institutional investors.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.